|

Irinotecan Hydrochloride Clinical Trials

9 actively recruiting trials across 5 locations

▲ +3 trials since July 2026

Also known as: CPT 11, CPT-11, CPT11, Campto, Camptosar +8 more

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 6

Top Sponsors

  • Sichuan Baili Pharmaceutical Co., Ltd.3
  • UNC Lineberger Comprehensive Cancer Center1
  • SWOG Cancer Research Network1
  • National Cancer Institute (NCI)1
  • NRG Oncology1

Indications

  • Cancer9
  • Biliary Tract Cancer2
  • Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma1
  • Stage II Pancreatic Cancer AJCC v81
  • Stage IV Small Intestinal Adenocarcinoma AJCC v81

Other3 trials

A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
Phase 3
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Phase 3
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Phase 3

Gilbert, Arizona2 trials

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Banner MD Anderson Cancer Center

Phase 3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Banner MD Anderson Cancer Center

Phase 3

Anchorage, Alaska1 trial

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Anchorage Associates in Radiation Medicine

Phase 2

Los Angeles, California1 trial

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Mattel Children's Hospital UCLA

Phase 3

Bethesda, Maryland1 trial

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

National Institutes of Health Clinical Center

Phase 1

Chapel Hill, North Carolina1 trial

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.